|
US8362325B2
(en)
|
2007-10-03 |
2013-01-29 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
|
MX2011000501A
(es)
*
|
2008-07-18 |
2011-05-23 |
Squibb Bristol Myers Co |
Composiciones monovalentes para union a cd28 y metodos de uso.
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
MX2014001238A
(es)
*
|
2011-08-05 |
2014-09-22 |
Genentech Inc |
Anticuerpos contra poliubiquitina y métodos de uso.
|
|
MX2017001946A
(es)
*
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
JP7080213B2
(ja)
*
|
2016-03-23 |
2022-06-03 |
スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド |
新規抗ｐｄ－ｌ１抗体
|
|
US20190106494A1
(en)
*
|
2016-06-13 |
2019-04-11 |
Askgene Pharma Inc. |
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
JP7148414B2
(ja)
|
2016-06-29 |
2022-10-05 |
チェックポイント セラピューティクス，インコーポレイテッド |
Ｐｄ－ｌ１特異的抗体およびそれを使用する方法
|
|
LT3592769T
(lt)
|
2017-03-09 |
2024-08-26 |
Genmab A/S |
Antikūnai, atpažįstantys pd-l1
|
|
AU2018236272B2
(en)
*
|
2017-03-15 |
2022-03-31 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
EA201900443A1
(ru)
|
2017-04-18 |
2020-03-06 |
Р-Фарм Оверсиз Инк. |
Антитело к pd-l1 и его применение
|
|
EP3672634A1
(en)
*
|
2017-08-24 |
2020-07-01 |
Invenra, Inc. |
Multivalent receptor-clustering agonist antibody constructs
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
WO2019084553A1
(en)
|
2017-10-27 |
2019-05-02 |
New York University |
ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
|
|
US12110332B2
(en)
|
2017-11-20 |
2024-10-08 |
Taizhou Mabtech Pharmaceutical Co., Ltd. |
Bifunctional fusion protein targeting CD47 and PD-L1
|
|
CA3084626A1
(en)
|
2017-12-04 |
2019-06-13 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
|
|
KR102845020B1
(ko)
*
|
2017-12-28 |
2025-08-12 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
|
WO2019179434A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/cd47 antibody molecules
|
|
CN112424225B
(zh)
|
2018-03-29 |
2023-08-11 |
桂林三金药业股份有限公司 |
抗pd-l1抗体及其用途
|
|
GB2596411B
(en)
|
2018-10-29 |
2023-09-20 |
Tigatx Inc |
Compositions and methods comprising IgA antibody constructs
|
|
CA3166328A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
|
AU2021322114A1
(en)
|
2020-08-04 |
2023-03-02 |
Exelixis, Inc. |
Multispecific binding agents and uses thereof
|
|
EP4475886A4
(en)
|
2022-02-09 |
2026-03-18 |
Exelixis Inc |
MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES
|